OPTINOSE INC (OPTN) Stock News
NASDAQ:OPTN - Nasdaq - US68404V2097 - Common Stock - Currency: USD
OPTN Latest News, Press Relases and Analysis
Paratek expands commercial portfolio with Optinose
The acquisition encompasses all outstanding shares of Optinose, including debt assumption and full payment of CVRs.
Mentions: AMZN
Home sales are stuck — and prices are still rising
Home sales are slowing again, and the culprit is no mystery — insert an “in this economy” joke here.
Mentions: RL
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -36.49% and 4.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MDWD
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 34.20% and 16.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: KPTI
OptiNose Stock Is Soaring Today: What's Going On?
OptiNose Inc (NASDAQ:OPTN) shares are trading higher Thursday after Paratek Pharmaceuticals announced a deal to acquire the company.
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -5.05% and 261%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CRNX
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, OPTN, AZEK, MESA on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders
Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year...
Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders
Mentions: BECN
Optinose Shares Soar After Merger Agreement With Paratek Pharmaceuticals: Retail Sentiment Takes Flight
Paratek will acquire Optniose's outstanding shares for $9 apiece in cash, representing a 50% premium to the stock’s closing trading price of $6 on March 19.
OPTN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Optinose, Inc. Is Fair to Shareholders
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat...
Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results
Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern Time...
Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results
Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern Time
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%...